Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03650881Withdrawn
Randomised, single-blind trial in acne vulgaris, sponsored by NYU Langone Health. Primary endpoint: Investigator Global Assessment at 12 weeks. Planned start Aug 2018; status: withdrawn.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03650881.